EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials

P J Gomes, J B Ciolino, P Arranz, A Gonzalo, N Fernández, G Hernández

Journal of Investigational Allergy and Clinical Immunology · 09.12.2024 · 34 (6) · 385-394

DOI: 10.18176/jiaci.0940 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Investigational Allergy and Clinical Immunology, online erschienen am 10.12.2024. Verfasst von P J Gomes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ora, Inc., Andover, Massachusetts, USA. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Ophthalmic Solutions, Piperidines, Benzimidazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic conjunctivitis is the most common type of ocular allergy.

Objective

The objective of this study was to evaluate the efficacy of a new once-daily, preservative-free, bilastine 0.6% eye drop formulation for the treatment of allergic conjunctivitis.

Methods

Two double-masked, vehicle-controlled, clinical studies (a phase 2 dose-ranging study and a phase 3 efficacy study) were conducted to assess the efficacy of bilastine ophthalmic solution for treatment of the signs and symptoms of allergic conjunctivitis. Both studies used the Ora-CAC® Conjunctival Allergen Challenge (CAC) model to enable observation of allergic responses under controlled conditions. Each study was analyzed separately and then combined to create an integrated data set.

Results

Efficacy was achieved for the primary efficacy endpoint of ocular itching with 3 bilastine concentrations (0.2%, 0.4%, and 0.6%) at 15 minutes and 8 hours after instillation. Bilastine 0.6% ophthalmic solution was also efficacious at 16 hours after instillation. Bilastine 0.6% ophthalmic solution demonstrated noninferiority to ketotifen 0.025% at the onset of action. According to the integrated data set, differences between vehicle and bilastine 0.6% after instillation were significant at all time points both at onset (15 minutes) and after a prolonged duration (16 hours).

Conclusion

This multitrial assessment suggests that bilastine 0.6% ophthalmic solution is efficacious for the treatment of the signs and symptoms of allergic conjunctivitis, with a rapid onset and prolonged duration of action, and has a favorable safety profile. The added convenience of once-daily dosing may contribute to adherence and improve quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conjunctivitis, AllergicOphthalmic SolutionsPiperidinesBenzimidazolesHumansMaleAdultFemaleMiddle AgedDouble-Blind MethodTreatment OutcomeYoung AdultAdolescentPreservatives, Pharmaceutical

Stichwörter der Autor:innen

Allergic conjunctivitisAntihistamineBilastineOnce-dailyPreservative-free

Substanzen

Ophthalmic SolutionsbilastinePiperidinesBenzimidazolesPreservatives, Pharmaceutical

Autor:innen und Institutionen

  • Ora, Inc., Andover, Massachusetts, USA.
  • Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
  • Research, Development and Innovation Department, FAES Farma, Bizkaia, Spain.

Zitieren

APA

Gomes, P. J., Ciolino, J. B., Arranz, P., Gonzalo, A., Fernández, N., & Hernández, G. (2024). Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials. Journal of Investigational Allergy and Clinical Immunology, 34(6), 385-394. https://doi.org/10.18176/jiaci.0940

Vancouver

Gomes PJ, Ciolino JB, Arranz P, Gonzalo A, Fernández N, Hernández G. Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials. Journal of Investigational Allergy and Clinical Immunology. 2024;34(6):385-394. doi:10.18176/jiaci.0940

BibTeX
@article{Gomes2024,
  author = {Gomes, P J and Ciolino, J B and Arranz, P and Gonzalo, A and Fernández, N and Hernández, G},
  title = {Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials},
  journal = {Journal of Investigational Allergy and Clinical Immunology},
  year = {2024},
  volume = {34},
  number = {6},
  pages = {385--394},
  doi = {10.18176/jiaci.0940}
}
Kostenlos starten →